top of page
Q3 2024 warning letter roundup with Asa Waldstein
Asa Waldstein
Guest Article
In his quarterly update, consultant Asa Waldstein identifies trends in FDA warning letters impacting manufacturers and marketers of dietary supplements.
At a Glance
Minor label violations, such as fact panel line thickness, continue to be cited in warning letters.
A NAD case involving a popular children's YouTube channel highlighted the complexities and need for material disclosure.
FDA warning letters underscore that elaborating on studies or posting about them on social media can be problematic.
bottom of page